PRECISION BIOSCIENCES INC (DTIL): Nasdaq/NYSE listing notice — Precision BioSciences transfers to Nasdaq Capital Market; gets 180-day grace for bid price compliance

PRECISION BIOSCIENCES INC

Transfer from Nasdaq Global Select to Nasdaq Capital Market effective Oct 26, 2023; ticker remains DTIL.
Nasdaq granted 180-day grace period until Apr 22, 2024 to regain $1.00 minimum bid price for 10 consecutive days.
Company notified Nasdaq it may effect a reverse stock split to cure the bid price deficiency.
If compliance not regained, Nasdaq will issue delisting notice; company may appeal to a Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PRECISION BIOSCIENCES INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 24, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. As a result of the Approval, the Company has been granted an additional 180-day grace period, or until April 22, 2024, t

View on SEC.gov

Browse all listing & compliance notices →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-055002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.